- Conditions
- Plaque Psoriasis
- Interventions
- Ixekizumab, Guselkumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,027 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 98
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 82 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 697–720
of 1,163
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hepatitis C
- Interventions
- Ribavirin, Mericitabine, Peginterferon Alfa-2a, Placebo, Telaprevir
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Long Beach, California • Sacramento, California + 12 more
- Conditions
- Venous Stasis Ulcer, Venous Leg Ulcer
- Interventions
- MTX-001 (human amniotic fluid)
- Biological
- Lead sponsor
- Merakris Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 12
- States / cities
- Tucson, Arizona • Castro Valley, California • Los Angeles, California + 8 more
- Conditions
- Post Menopausal Osteoporosis
- Interventions
- Abaloparatide Transdermal (50 mcg), Abaloparatide Transdermal (100 mcg), Abaloparatide Transdermal (150 mcg), Abaloparatide Injection (80 mcg), Abaloparatide Placebo
- Drug
- Lead sponsor
- Radius Health, Inc.
- Industry
- Eligibility
- Up to 85 Years · Female only
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 3
- States / cities
- Lakewood, Colorado • Atlanta, Georgia • Bethesda, Maryland
- Conditions
- Infra-orbital Hollows, Skin Quality Improvement
- Interventions
- RhPDGF-BB, Normal Saline
- Biological · Drug
- Lead sponsor
- Lynch Regenerative Medicine
- Network
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 6
- States / cities
- Newport Beach, California • Santa Monica, California • Chicago, Illinois + 3 more
- Conditions
- Psoriatic Arthritis
- Interventions
- Etanercept, Methotrexate, Placebo to Etanercept, Placebo to Methotrexate
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 851 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 55
- States / cities
- Tuscaloosa, Alabama • Glendale, Arizona • Mesa, Arizona + 50 more
- Conditions
- Graves' Disease
- Interventions
- Experimental: YB-101, Placebo YB-101
- Drug
- Lead sponsor
- Yarrow Bioscience, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 232 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 29
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 26 more
- Conditions
- Arthritis, Psoriatic
- Interventions
- placebo, ustekinumab 45 mg, ustekinumab 90 mg
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Los Angeles, California + 22 more
- Conditions
- Asthma
- Interventions
- Omalizumab, Inhaled Corticosteroid Boost Therapy (ICS), Placebo omalizumab, Placebo fluticasone
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 478 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 8
- States / cities
- Denver, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 5 more
- Conditions
- Primary Hyperoxaluria Type 3
- Interventions
- DCR-PHXC, Sterile Normal Saline (0.9% NaCl)
- Drug
- Lead sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Rochester, Minnesota • New York, New York
- Conditions
- Coronavirus, Covid19
- Interventions
- bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV), AZD7442 (IM), SNG001, Camostat, BMS-986414 + BMS-986413, SAB-185 (3,840 Units/kg), SAB-185 (10,240 Units/kg), CASIRIVIMAB + IMDEVIMAB, Placebo for Bamlanivimab 7000mg, Placebo for Bamlanivimab 700mg, Placebo for BRII-196+BRII-198, Placebo for SNG001, Placebo for Camostat, Placebo for SAB-185 (low dose), Placebo for BMS-986414 + BMS-986413, Placebo for AZD7442 (IV), Placebo for AZD7442 (IM), Placebo for SAB-185 (high dose), bamlanivimab 700mg
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 4,044 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 207
- States / cities
- Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 143 more
- Conditions
- Atopic Dermatitis
- Interventions
- MOR106, Placebo
- Drug
- Lead sponsor
- Lakefront Biotherapeutics NV
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 14
- States / cities
- Fountain Valley, California • Huntington Beach, California • Los Angeles, California + 11 more
- Conditions
- HIV I Infection
- Interventions
- VIR-1111, Placebo
- Biological · Drug
- Lead sponsor
- Vir Biotechnology, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 3
- States / cities
- Miami, Florida • Seattle, Washington • Madison, Wisconsin
- Conditions
- Crohn's Disease
- Interventions
- placebo for risankizumab, risankizumab IV, risankizumab SC
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 16 Years to 80 Years
- Enrollment
- 931 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 117
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 94 more
- Conditions
- Trigeminal Neuropathy
- Interventions
- Erenumab-Aooe, Placebo
- Drug · Other
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Efpeglenatide SAR439977, Placebo, Background therapy: Metformin alone or in combination with SU
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 20 more
- Conditions
- Cachexia
- Interventions
- Placebo comparator, SUN11031 20 μg/kg, SUN11031 40 μg/kg
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 227 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 11
- States / cities
- Waterbury, Connecticut • Clearwater, Florida • Largo, Florida + 8 more
- Conditions
- Hereditary Hemochromatosis
- Interventions
- LJPC-401, Placebo
- Drug
- Lead sponsor
- La Jolla Pharmaceutical Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 18
- States / cities
- North Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 15 more
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- Atacicept 75 milligram (mg), Atacicept 150 mg, Placebo
- Drug
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 30
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Anaheim, California + 24 more
- Conditions
- Acute Pericarditis
- Interventions
- Anakinra, Placebo
- Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Rheumatoid Arthritis
- Interventions
- Sarilumab, Placebo, Golimumab, methotrexate (MTX), Folic/folinic acid
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 4
- States / cities
- Freehold, New Jersey • New York, New York • Jackson, Tennessee + 1 more
- Conditions
- Osteoarthritis, Knee
- Interventions
- Pentosan Polysulfate Sodium twice weekly, Placebo (Sodium Chloride Injection, 0.9%), Pentosan Polysulfate Sodium Fixed Dose, Pentosan Polysulfate Sodium once weekly
- Drug
- Lead sponsor
- Paradigm Biopharmaceuticals USA (INC)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 602 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 29
- States / cities
- Tempe, Arizona • Tucson, Arizona • Cerritos, California + 20 more
- Conditions
- Systemic Lupus Erythematosus, Lupus Erythematosus, Systemic
- Interventions
- TAK-079, TAK-079 Placebo
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 19
- States / cities
- Anniston, Alabama • Birmingham, Alabama • La Jolla, California + 15 more
- Conditions
- Overweight, Healthy Subjects
- Interventions
- SAR441255, placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee